Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting

Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosusBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage ...
Lupus Foundation of America

Novel Stromal Cell Study in Lupus Reaches Critical Milestone

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...
Medscape

In Vivo CAR T-Cell Therapy Shows Potential in Refractory SLE

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...
Business Insider

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient ...
Yahoo

Root Cause of Lupus Found in a 'Tug-of-War' Over a Critical White Cell

Add Yahoo as a preferred source to see more of our stories on Google. Two white cells stuck together The autoimmune disease, lupus – officially known as systemic lupus erythematosus (SLE) – is a ...
Healio

'I am optimistic': Lupus pipeline features promising B-cell depletion therapies

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Obinutuzumab and ianalumab are two promising B-cell depleting therapies on the horizon for lupus, ...